Search
Axsome Therapeutics Inc
AXSMAdd to Watchlist
217.990USD
-16.650-7.10%
Close 07-31 16:00（ET）Quotes delayed by 15 min
11.22BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Axsome Therapeutics Inc is 8.67, ranking 12 out of 155 in the Pharmaceuticals industry. The average price target is 185.00, with a high of 205.00 and a low of 148.00.
Analyst Rating
Based on
22
analysts
Buy
Current Rating
276.286
Target Price
+21.49%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Axsome Therapeutics Inc
AXSM
22
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Axsome Therapeutics Inc's expected revenue for the next quarter?
Axsome Therapeutics Inc's expected revenue is 221.03M.
What is Axsome Therapeutics Inc's price target?
Analysts forecast that Axsome Therapeutics Inc's price target is USD 185.00, with the highest forecast at USD 205.00 and the lowest forecast at USD 148.00.
How have Axsome Therapeutics IncAXSM's recent earnings per share performed?
The market expectation was USD -1.26, while Axsome Therapeutics IncAXSM's earnings per share (EPS) for the previous quarter was USD -0.56. EPS for the next quarter is expected at USD -0.84.
What is the analyst rating for Axsome Therapeutics Inc?
Based on the ratings of Axsome Therapeutics Inc's stock from 22 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.